Friday, Dec 17, 1999

Phase III Anti-IgE Asthma Clinical Trials Show Positive Preliminary Results

South San Francisco, Calif. -- December 17, 1999 --

Genentech, Inc. (NYSE: DNA) today announced preliminary positive results from the Phase III asthma efficacy trials for anti-IgE (rhuMAb-E25). Genentech, Inc., Novartis Pharma AG and Tanox, Inc. are collaborating on Phase III clinical development of anti-IgE in development for allergic asthma and seasonal allergic rhinitis. The companies intend to move forward with a biologics license application filing in the United States and registration in Europe by mid-year 2000.

The companies plan to complete a full analysis of the Phase III asthma data by first quarter 2000, and hope to present results at the American Academy of Allergy Asthma and Immunology (AAAAI) in San Diego in March. Earlier this year, positive Phase III seasonal allergic rhinitis results were presented at the 20th Annual Nordic Congress on Allergology.

The safety and efficacy of this compound will be determined by the U.S. Food and Drug Administration as well as other regulatory authorities as part of the market registration process.

Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and markets human pharmaceuticals for significant unmet medical needs. Twelve of the currently marketed biotechnology products stem from Genentech science. Genentech markets seven products directly in the United States. The company has headquarters in South San Francisco, California and is traded on the New York Stock Exchange under the symbol DNA.

# # #